CliffBio
small molecule

BROMFENAC SODIUM

BROMFENAC SODIUM

Loss of exclusivity—loss of exclusivity
CompanyLupin →See this company's full patent-cliff portfolio

Drug detail

Brand nameBROMFENAC SODIUM
Active ingredientBROMFENAC SODIUM
StrengthEQ 0.09% ACID
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalAugust 2023
Marketing statusRX

More from Lupin

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.